secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001104659-26-005035
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharmaceuticals suspends $100M ATM equity offering program
-----------------------------------------------------------------

- Suspended $100M at-the-market offering; zero shares sold prior to suspension.
- Company notified Jefferies; no sales until new prospectus supplement or registration statement filed.
- Sale Agreement remains in full force and effect despite suspension.
- Company cites proposed registered underwritten public offering as context.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926005035/0001104659-26-005035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926005035/tm263501d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-005035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer